NBY
Price
$0.58
Change
-$0.01 (-1.69%)
Updated
Jun 6 closing price
Capitalization
3.43M
PMN
Price
$0.48
Change
-$0.00 (-0.00%)
Updated
Jun 6 closing price
Capitalization
15.72M
70 days until earnings call
Interact to see
Advertisement

NBY vs PMN

Header iconNBY vs PMN Comparison
Open Charts NBY vs PMNBanner chart's image
NovaBay Pharmaceuticals
Price$0.58
Change-$0.01 (-1.69%)
Volume$20.5K
Capitalization3.43M
ProMIS Neurosciences
Price$0.48
Change-$0.00 (-0.00%)
Volume$58K
Capitalization15.72M
NBY vs PMN Comparison Chart
Loading...
NBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PMN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NBY vs. PMN commentary
Jun 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NBY is a Buy and PMN is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 09, 2025
Stock price -- (NBY: $0.56 vs. PMN: $0.48)
Brand notoriety: NBY and PMN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NBY: 42% vs. PMN: 110%
Market capitalization -- NBY: $3.43M vs. PMN: $15.72M
NBY [@Biotechnology] is valued at $3.43M. PMN’s [@Biotechnology] market capitalization is $15.72M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NBY’s FA Score shows that 1 FA rating(s) are green whilePMN’s FA Score has 0 green FA rating(s).

  • NBY’s FA Score: 1 green, 4 red.
  • PMN’s FA Score: 0 green, 5 red.
According to our system of comparison, NBY is a better buy in the long-term than PMN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NBY’s TA Score shows that 5 TA indicator(s) are bullish while PMN’s TA Score has 4 bullish TA indicator(s).

  • NBY’s TA Score: 5 bullish, 4 bearish.
  • PMN’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, both NBY and PMN are a good buy in the short-term.

Price Growth

NBY (@Biotechnology) experienced а +0.43% price change this week, while PMN (@Biotechnology) price change was -3.28% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.11%. For the same industry, the average monthly price growth was +10.01%, and the average quarterly price growth was -2.16%.

Reported Earning Dates

PMN is expected to report earnings on Aug 18, 2025.

Industries' Descriptions

@Biotechnology (+4.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PMN($15.7M) has a higher market cap than NBY($3.43M). PMN has higher P/E ratio than NBY: PMN (5.34) vs NBY (0.02). NBY YTD gains are higher at: -6.406 vs. PMN (-49.356). PMN has higher annual earnings (EBITDA): -391.76K vs. NBY (-6.52M). PMN has more cash in the bank: 21.6M vs. NBY (776K). NBY has less debt than PMN: NBY (1.26M) vs PMN (4.05M). NBY has higher revenues than PMN: NBY (13.8M) vs PMN (0).
NBYPMNNBY / PMN
Capitalization3.43M15.7M22%
EBITDA-6.52M-391.76K1,665%
Gain YTD-6.406-49.35613%
P/E Ratio0.025.340%
Revenue13.8M0-
Total Cash776K21.6M4%
Total Debt1.26M4.05M31%
FUNDAMENTALS RATINGS
NBY vs PMN: Fundamental Ratings
NBY
PMN
OUTLOOK RATING
1..100
23
VALUATION
overvalued / fair valued / undervalued
1..100
13
Undervalued
94
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10093
PRICE GROWTH RATING
1..100
8290
P/E GROWTH RATING
1..100
5899
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NBY's Valuation (13) in the Biotechnology industry is significantly better than the same rating for PMN (94) in the null industry. This means that NBY’s stock grew significantly faster than PMN’s over the last 12 months.

NBY's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as PMN (100) in the null industry. This means that NBY’s stock grew similarly to PMN’s over the last 12 months.

PMN's SMR Rating (93) in the null industry is in the same range as NBY (100) in the Biotechnology industry. This means that PMN’s stock grew similarly to NBY’s over the last 12 months.

NBY's Price Growth Rating (82) in the Biotechnology industry is in the same range as PMN (90) in the null industry. This means that NBY’s stock grew similarly to PMN’s over the last 12 months.

NBY's P/E Growth Rating (58) in the Biotechnology industry is somewhat better than the same rating for PMN (99) in the null industry. This means that NBY’s stock grew somewhat faster than PMN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NBYPMN
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 12 days ago
81%
Bullish Trend 12 days ago
80%
Momentum
ODDS (%)
Bearish Trend 12 days ago
90%
Bearish Trend 12 days ago
90%
MACD
ODDS (%)
Bearish Trend 12 days ago
90%
Bullish Trend 12 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 12 days ago
90%
Bearish Trend 12 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 12 days ago
90%
Bearish Trend 12 days ago
90%
Advances
ODDS (%)
Bullish Trend 21 days ago
82%
Bullish Trend 13 days ago
82%
Declines
ODDS (%)
Bearish Trend 12 days ago
90%
Bearish Trend 21 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 12 days ago
90%
Bullish Trend 12 days ago
90%
Aroon
ODDS (%)
Bullish Trend 12 days ago
86%
Bearish Trend 12 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
NBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PMN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL200.420.21
+0.10%
Apple
SPY587.73-3.42
-0.58%
SPDR® S&P 500® ETF
BTC.X107802.330000-1192.312500
-1.09%
Bitcoin cryptocurrency
TSLA356.90-5.99
-1.65%
Tesla
GME31.21-3.80
-10.85%
GameStop Corp

NBY and

Correlation & Price change

A.I.dvisor indicates that over the last year, NBY has been closely correlated with CDTX. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if NBY jumps, then CDTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBY
1D Price
Change %
NBY100%
-0.58%
CDTX - NBY
93%
Closely correlated
-5.46%
NCNA - NBY
93%
Closely correlated
-3.85%
WINT - NBY
92%
Closely correlated
+5.12%
SNPX - NBY
91%
Closely correlated
-10.74%
RNAC - NBY
91%
Closely correlated
+3.65%
More

PMN and

Correlation & Price change

A.I.dvisor indicates that over the last year, PMN has been loosely correlated with BBIO. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if PMN jumps, then BBIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PMN
1D Price
Change %
PMN100%
-10.13%
BBIO - PMN
40%
Loosely correlated
-2.54%
ABOS - PMN
29%
Poorly correlated
N/A
GALT - PMN
25%
Poorly correlated
-1.53%
NBY - PMN
25%
Poorly correlated
-0.58%
LIXT - PMN
25%
Poorly correlated
+0.75%
More